To accelerate clinical applications of laboratory findings relevant to improved diagnosis and management of leukemia, lymphoma, myeloma and other hematopoietic malignancies. Proposals of particular interest will address:
1. Personalized medicine approach for cancer treatment.
2. Development of novel therapies and/or novel therapeutic strategies including those that target mutational and epigenetic events within the microenvironment.
3. Improvements of safety and efficacy of stem cell transplantation.
4. Long-term outcome assessment following therapies.
5. Progress in understanding neoplastic stem cell growth and differentiation as well as cancer cell/microenivronmental interactions especially with translation to novel therapies.
6. The advancement of therapies in pediatric indications with novel approaches or to minimize therapy-related effects of existing treatments.
The society welcomes applications from both US citizens and noncitizens who hold a PhD, MD, DVM or equivalent degree and have been appointed not-for-profit institution at the time the funding commences.
Up to $200,000 (including direct costs and a maximum overhead of $19,982) per year for three years.
Sep. 29, 2017 (letters of intent); Nov. 15, 2017 (full application)
May 2018 (award notification); July 1, 2018 (award begins)
For more information visit http://www.lls.org/research/translational-research-program